Myelodysplastic syndrome laboratory findings: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(Mahshid)
 
(10 intermediate revisions by one other user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{NM}}
{{CMG}}; {{AE}} {{NM}}
==Overview==
==Overview==
Laboratory findings consistent with the diagnosis of myelodysplastic syndrome include abnormal complete blood count, peripheral blood smear, cytogenetic analysis, immunohistochemistry, and bone marrow biopsy.<ref name=cancergov5>Tests to examine and diagnose myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed on December 14, 2015</ref>  
Laboratory findings consistent with the diagnosis of myelodysplastic syndrome include abnormal [[complete blood count]], [[peripheral blood smear]], cytogenetic analysis, and [[immunohistochemistry]].<ref name=cancergov5>Tests to examine and diagnose myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed on December 14, 2015</ref><ref name=Macrocytosis>Causes of macrocytosis. Wikipedia (2015). https://en.wikipedia.org/wiki/Macrocytosis. Accessed on December 14, 2015</ref><ref name=Basophilic>Basophilic stippling. Wikipedia (2015). https://en.wikipedia.org/wiki/Basophilic_stippling. Accessed on December 14, 2015</ref><ref name=Howell>Causes of Howell-Jolly body. Wikipedia (2015). https://en.wikipedia.org/wiki/Howell%E2%80%93Jolly_body. Accessed on December 14, 2015</ref><ref name=Pseudopelger>Acquired or pseudo-Pelger-Huët anomaly. Wikipedia (2015). https://en.wikipedia.org/wiki/Pelger%E2%80%93Huet_anomaly. Accessed on December 14, 2015</ref><ref name=Librepathology2>Cytogenetics of myelodysplastic syndromes. Librepathology (2015). http://librepathology.org/wiki/index.php/Myelodysplastic_syndromes. Accessed on December 8, 2015</ref><ref name="Haase2008">{{cite journal|last1=Haase|first1=Detlef|title=Cytogenetic features in myelodysplastic syndromes|journal=Annals of Hematology|volume=87|issue=7|year=2008|pages=515–526|issn=0939-5555|doi=10.1007/s00277-008-0483-y}}</ref><ref name="TricotWolf-Peeters1984">{{cite journal|last1=Tricot|first1=G.|last2=Wolf-Peeters|first2=C. De|last3=Hendrickx|first3=B.|last4=Verwilghen|first4=R. L.|title=Bone marrow histology in myelodysplastic syndromes.|journal=British Journal of Haematology|volume=57|issue=3|year=1984|pages=423–430|issn=0007-1048|doi=10.1111/j.1365-2141.1984.tb02916.x}}</ref>
==Laboratory Findings==
==Laboratory Findings==
Laboratory findings consistent with the diagnosis of myelodysplastic syndrome include abnormal complete blood count, peripheral blood smear, cytogenetic analysis, immunohistochemistry, and bone marrow biopsy.<ref name=cancergov5>Tests to examine and diagnose myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed on December 14, 2015</ref>  
Laboratory findings consistent with the diagnosis of myelodysplastic syndrome include abnormal [[complete blood count]], [[peripheral blood smear]], cytogenetic analysis, [[immunohistochemistry]], and [[bone marrow biopsy]].<ref name=cancergov5>Tests to examine and diagnose myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed on December 14, 2015</ref>  
===Complete Blood Count===
===Complete Blood Count===
On [[complete blood count]], characteristic findings of myelodysplastic syndrome include:<ref name=cancergov5>Tests to examine and diagnose myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed on December 14, 2015</ref>  
On [[complete blood count]], characteristic findings of myelodysplastic syndrome include:<ref name=cancergov5>Tests to examine and diagnose myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed on December 14, 2015</ref>  
Line 18: Line 18:
*[[Howell-Jolly body]]
*[[Howell-Jolly body]]
*Acquired or pseudo-Pelger-Huët anomaly
*Acquired or pseudo-Pelger-Huët anomaly
===Cytogenetic analysis===
===Cytogenetic Analysis===
===Blood chemistry studies===
On cytogenetic analysis, characteristic findings of myelodysplastic syndrome include:<ref name=Librepathology2>Cytogenetics of myelodysplastic syndromes. Librepathology (2015). http://librepathology.org/wiki/index.php/Myelodysplastic_syndromes. Accessed on December 8, 2015</ref><ref name="Haase2008">{{cite journal|last1=Haase|first1=Detlef|title=Cytogenetic features in myelodysplastic syndromes|journal=Annals of Hematology|volume=87|issue=7|year=2008|pages=515–526|issn=0939-5555|doi=10.1007/s00277-008-0483-y}}</ref>
===Bone marrow aspiration and biopsy===
*Deletions within the long arm of chromosome 5
Abnormalities include:
*Deletions within the short arm of chromosome 17
* [[neutropenia]], [[anemia]] and [[thrombocytopenia]] (low cell counts of white and red blood cells, and platelets, respectively)
*Monosomy 7
* abnormal granules in cells, abnormal nuclear shape and size
*Monosomy 8
* [[chromosome|chromosomal]] abnormalities, including [[chromosomal translocation]]s and abnormal chromosome number.
* [[Full blood count]] and examination of [[blood film]]. The [[blood film]] morphology can provide clues about [[hemolytic anemia]], clumping of the [[platelets]] leading to spurious [[thrombocytopenia]], or [[leukemia]].
* Blood tests to eliminate other common causes of [[cytopenias]], such as [[lupus]], [[hepatitis]], [[B12]], [[folate]], or other [[vitamin]] deficiencies, [[renal failure]] or [[heart failure]], [[HIV]], [[hemolytic anemia]], [[monoclonal gammopathy]].  Age-appropriate cancer screening should be considered for all [[anemic]] patients.
====PAS stain====
Dysplasia can affect all three lineages seen in the bone marrow. The best way to diagnose dysplasia is by morphology and special stains (PAS) used on the bone marrow aspirate and peripheral blood smear. 
Dysplasia in the myeloid series is defined by:
*Granulocytic series
*# Hypersegmented neutrophils (also seen in Vit B12/Folate deficiency)
*# Hyposegmented neutrophils (Pseudo-Pelger Huet)
*# Hypogranular neutrophils or pseudo Chediak Higashi large granules
*# Dimorphic granules (basophilic and eosinophilic granules) within eosinophils
* Erythroid series
*# Binucleated erythroid percursors and karyorrhexis
*# Erythroid nuclear budding
*# Erythroid nuclear strings or internuclear bridging (also seen in congenital dyserythropoietic anemias)
*# PAS (globular in vacuoles or diffuse cytoplasmic staining) within erythroid precursors in the bone marrow aspirate (has no bearing on paraffin fixed bone marrow biopsy).  Note: One can see PAS vacuolar positivity in L1 and L2 blasts (AFB classification; the L1 and L2 nomenclature is not used in the WHO classification)
*# Ringed sideroblasts seen on Prussian blue iron stain (10 or more iron granules encircling 1/3 or more of the nucleus and >15% ringed sideroblasts when counted amongst red cell precursors)
* Megakaryocytic series (can be the most subjective)
*# Hyposegmented nuclear features in platelet producing megakaryocytes (lack of lobation)
*# Hypersegmented (osteoclastic appearing) megakaryocytes
*# Ballooning of the platelets (seen with interference contrast microscopy)
 
Other stains can help in special cases (PAS and napthol ASD chloroacetate esterase positivity) in eosinophils is a marker of abnormality seen in chronic eosinophilic leukemia and is a sign of aberrancy.
 
MDS can appear a lot like megaloblastic anemia however megaloblastic anemia has cell lysis thereby causing an increase in the bilirubin and LDH whereas, in MDS, these aren't elevated. 
 
On the bone marrow biopsy high grade dysplasia (RAEB-I and RAEB-II) may show atypical localization of immature precursors (ALIPs) which are islands of immature cells/(blasts) clustering together.  This morphology can be difficult to recognize from treated leukemia and recovering immature normal marrow elements.  Also topographic alteration of the nucleated erythroid cells can be seen in early myelodysplasia (RA and RARS), where normoblasts are seen next to bony trabeculae instead of forming normal interstitially placed erythroid islands.  ALIP is thought to be a preleukemic harbinger and associated with a poor outcome in RA and RARS. 
 
Hypoplastic MDS has a cellularity of less than 25-30% and shares features that appear to overlap with aplastic anemia and paroxysmal nocturnal hemoglobinuria (PNH).  In these patients the administration of anti-thymocyte globulin (ATG) and cyclosporine have produced response rates of 44% and 84% respectively.  The presence of a PNH clone, bone marrow hypocellularity and <5% bone marrow blasts are positive predictors of response to immunomodulation. 
 
Malfunctions can occur in the cells of MDS patients.  These can manifest as poor platelet aggregation or impaired neutrophil chemotaxis.  One of the more phenotypically obvious acquired red blood cell disorders in MDS is alpha thalassemia which is usually associated with a microcytic and hypochromic erythrocyte indices and with somatic point mutation in ATRX, a chromatin remodeling factor encoded by the X-chromosome. 
 
Myelodysplasia is a diagnosis of exclusion and must be made after proper determination of iron stores, [[vitamin]] deficiencies, and nutrient deficiencies are ruled out.  Also congenital diseases such as congenital dyserthropoietic anemia (CDA I through IV) has been recognized, [[Sideroblastic anemia|Pearson's syndrome (sideroblastic anemia)]], Jacobson's syndrome, ALA (aminolevulinic acid) enzyme deficiency, and other more esoteric enzyme deficiencies are known to give a pseudomyelodysplastic picture in one of the cell lines, however, all three cell lines are never morphologically dysplastic in these entities with the exception of chloramphenicol, arsenic toxicity and other poisons.
 
All of these conditions are characterized by abnormalities in the production of one or more of the cellular components of blood ([[red blood cell|red cell]]s, [[white blood cell|white cell]]s other than [[lymphocyte]]s and [[platelets]] or their progenitor cells, [[megakaryocyte]]s).
 
==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
Line 69: Line 32:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 02:49, 27 November 2017

Myelodysplastic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelodysplastic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelodysplastic syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelodysplastic syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelodysplastic syndrome laboratory findings

CDC on Myelodysplastic syndrome laboratory findings

Myelodysplastic syndrome laboratory findings in the news

Blogs on Myelodysplastic syndrome laboratory findings

Directions to Hospitals Treating Myelodysplastic syndrome

Risk calculators and risk factors for Myelodysplastic syndrome laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Overview

Laboratory findings consistent with the diagnosis of myelodysplastic syndrome include abnormal complete blood count, peripheral blood smear, cytogenetic analysis, and immunohistochemistry.[1][2][3][4][5][6][7][8]

Laboratory Findings

Laboratory findings consistent with the diagnosis of myelodysplastic syndrome include abnormal complete blood count, peripheral blood smear, cytogenetic analysis, immunohistochemistry, and bone marrow biopsy.[1]

Complete Blood Count

On complete blood count, characteristic findings of myelodysplastic syndrome include:[1]

Peripheral Blood Smear

On peripheral blood smear, characteristic findings of myelodysplastic syndrome include:[2][3][4][5]

  • Macro-ovalocytes
  • Basophilic stippling
  • Howell-Jolly body
  • Acquired or pseudo-Pelger-Huët anomaly

Cytogenetic Analysis

On cytogenetic analysis, characteristic findings of myelodysplastic syndrome include:[6][7]

  • Deletions within the long arm of chromosome 5
  • Deletions within the short arm of chromosome 17
  • Monosomy 7
  • Monosomy 8

References

  1. ↑ 1.0 1.1 1.2 Tests to examine and diagnose myelodysplastic syndromes. National Cancer Institute 2015. http://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Accessed on December 14, 2015
  2. ↑ 2.0 2.1 Causes of macrocytosis. Wikipedia (2015). https://en.wikipedia.org/wiki/Macrocytosis. Accessed on December 14, 2015
  3. ↑ 3.0 3.1 Basophilic stippling. Wikipedia (2015). https://en.wikipedia.org/wiki/Basophilic_stippling. Accessed on December 14, 2015
  4. ↑ 4.0 4.1 Causes of Howell-Jolly body. Wikipedia (2015). https://en.wikipedia.org/wiki/Howell%E2%80%93Jolly_body. Accessed on December 14, 2015
  5. ↑ 5.0 5.1 Acquired or pseudo-Pelger-Huët anomaly. Wikipedia (2015). https://en.wikipedia.org/wiki/Pelger%E2%80%93Huet_anomaly. Accessed on December 14, 2015
  6. ↑ 6.0 6.1 Cytogenetics of myelodysplastic syndromes. Librepathology (2015). http://librepathology.org/wiki/index.php/Myelodysplastic_syndromes. Accessed on December 8, 2015
  7. ↑ 7.0 7.1 Haase, Detlef (2008). "Cytogenetic features in myelodysplastic syndromes". Annals of Hematology. 87 (7): 515–526. doi:10.1007/s00277-008-0483-y. ISSN 0939-5555.
  8. ↑ Tricot, G.; Wolf-Peeters, C. De; Hendrickx, B.; Verwilghen, R. L. (1984). "Bone marrow histology in myelodysplastic syndromes". British Journal of Haematology. 57 (3): 423–430. doi:10.1111/j.1365-2141.1984.tb02916.x. ISSN 0007-1048.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Myelodysplastic_syndrome_laboratory_findings&oldid=1395341"